Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT1194D CAR-T in R/R B-Cell Neoplasms
NCT07200479Phase 1Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Oct 2025
- Primary completion
- Jun 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT1194D in B-cell non-Hodgkin lymphoma and B cell acute lymphoblastic leukemia (B-ALL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Dose-Limiting Toxicities at 12 months, Treatment-Related Adverse Events at 12 months and 2 more. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
CT1194D
03
Conditions
B-cell non-Hodgkin lymphomaB cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07200479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07200479.